Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(4):270-274
DOI: 10.5428/pcar20180409
Analysis of irrational medication of infusion therapy in cancer patients
1. HUANG XianChuan(Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University,Fujian Zhangzhou 363000, China HXC905@163.com)
2. WANG Jing(Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University,Fujian Zhangzhou 363000, China )
3. XIE LiJun(Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University,Fujian Zhangzhou 363000, China 269173201@qq.com)
4. CAI XiaoYan(Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University,Fujian Zhangzhou 363000, China )
ABSTRACT  Objective: To promote the safety and quality of intravenous infusion therapy in cancer patients and avoid risks associated with infusion therapy. Methods: Medical advices concerning intravenous infusion were collected from 3217 cancer patients admitted in the Department of Oncology of Zhangzhou Hospital Affiliated to Fujian Medical University in 2016. Proper medication with infusion therapy was reviewed and analyzed from the aspects of infusion rate, intravenous nutrition, infusion procedures, interval liquid, the prevention and treatment of adverse drug reactions (ADRs) and the incompatibility of drugs. Results: Totally, there were 185 inappropriate medical orders, of which 63 medical orders were of unreasonable infusion rate (34.1%), 48 were of improper intravenous nutrition (25.9%), 33 were of inappropriate prevention and treatment measures against ADRs (17.8%), 17 were of improper procedures of infusion (9.2%), 15 were of inappropriate use of interval fluid (8.1%), and 9 were of other improper procedures of infusion (4.9%). Conclusion: Problems still exist concerning fluid infusion in the Department of Oncology of the hospital. With this reason, it is recommended that efforts should be made to intensity clinical pharmaceutical monitoring, so as to standardize infusion procedures.
Welcome to PCAR! You are the number 66 reader of this article!
Please cite this article as:
HUANG XianChuan,WANG Jing,XIE LiJun,CAI XiaoYan,. Analysis of irrational medication of infusion therapy in cancer patients[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 270-274.
References:
1. ZHAO FangYun, DING Li,WANG Li, et al. Analysis of concentrations and infusion rates of 275 commonly-used intravenous infusions in our hospital[J]. Chin Hosp Pharm J, 2017, 37(14):1405-1408. In Chinese with English abstract.
2. YANG BaoFeng. Pharmacology[M]. 8th ed.Beijing: People’s Medical Publishing House, 2013:20, 218. In Chinese.
3. LIN Tong, HUANG LeShan, QIU RiXiang, et al. Analysis of the cases of chemotherapeutic medication in PIVAS[J]. Chin Hosp Pharm J, 2013,33(22):1892-1895. In Chinese.
4. WU YongPei, JIAO YaHui. Guidelines for clinical pharmacy intravenous admixture and use[M]. Beijing:People’s Medical Publishing House, 2010:28. In Chinese.
5. LI Ning,YU JianChun, CAI Wei. The therapy of clinical parenteral and enteral nutrition support[M]. Beijing: Chinese Medical Electronic Audio-Visual Publishing House, 2012:59, 293, 49. In Chinese.
6. LI WenWu, WANG ChangZhi, MA XueJiao, et al. Analysis of the ADR/ADE reports induced by compound amino acid injections (18AA) from 2004 to 2013[J]. China Pharmacy, 2016,27(9):1166-1169. In Chinese with English abstract.
7. FANG Yu, YANG Rui, XIN XiaoWei, et al. A survey of nutritional support in gastrointestinal cancer patients[J]. Parenter Enteral Nutr, 2014, 21 (1):31-34. In Chinese with English abstract.
8. ZHAO LiHua. Analysis of application of parenteral nutrition of inpatients in Anhui Provincial Corps Hospital of Chinese People’s Armed Police from 2014 to 2016[J]. Eval Anal Drug-Use Hosp China, 2017, 17(7):944-946. In Chinese with English abstract.
9. Bozzetti F,Arends J,Lundholm K, et al. ESPEN Guidelines on parenteral nutrition:non-surgical oncology[J]. Clin Nutr,2009,28(4):445-454.
10. Pharmaceutical Association of Guangdong Province. Consensus on clinical pharmacy of parenteral nutrition (2nd ed)[J]. Pharm Today, 2017, 27(5):289-303. In Chinese.
11. Expert committee of CSCO tumor patients nutrition therapy. Experts consensus on nutritional therapy in patients with malignant tumor[J]. Chin Clin Oncol, 2012, 17(1):59-73. In Chinese.
12. ZHAO HuaYe,CAO JunLing. Study on the effects of Aidi injection on the pharmacokinetics of cisplatin and its effects on liver and kidney toxicity induced by cisplatin[D]. Beijing: Beijing University of Chinese Medicine,2016:75-76. In Chinese with English abstract.
13. HUANG XianChuan, XIE LiJun,HUANG HuiJiao. Rational allocation and use of intravenous anti-tumor drugs[J]. Eval Anal Drug-Use Hosp China, 2014, 14(8):746-748. In Chinese with English abstract.
14. YU HongLing. Pharmaceutical care for intravenous administration of cytotoxic drugs by PIVAS pharmacists[J]. China Pharmacy, 2012,23(46):4399-4401. In Chinese with English abstract.
15. XU YanGui, ZHU LiQin, DU Yi, et al. Analysis of the relationship between infusion-related adverse events and dripping rate in medical institutions in Tianjin[J]. China Pharmacy, 2014, 25(2):153-155. In Chinese with English abstract.
16. ZHENG JieYuan, SHAO ZhiYu. Management of intravenous infusion rate under JCI concept[J]. Chin Hosp Pharm J, 2015, 35(18):1698-1700. In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口